Medical Research Council: $4.9 Million Boost for Ground Breaking Cystic Fibrosis Treatment

A £3.1 million award from the Medical Research Council (MRC) and the National Institute for Health Research (NIHR) will enable a UK consortium to move ahead with efficacy testing of its inhaled gene therapy for cystic fibrosis. A Phase II clinical trial of the treatment developed by the UK Cystic Fibrosis (CF) Gene Therapy Consortium will start this spring. The MRC has awarded a further £1.2 million for a second study looking at a more advanced version of the therapy that uses a modified virus to carry the replacement gene into the lungs.

Back to news